Xia Yuan1, Yi He1, Chenhui Luo2, Wei Wang3. 1. Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, China. 2. Scientific Research Office, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, China. 3. Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, China. wangweizzly@sina.com.
Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. According to reports, leukotriene B4 receptor 2 (LTB4R2, also known as BLT2), a chemokine receptor, is upregulated in different tumors. However, the correlation between BLT2 expression and its prognostic value in ccRCC remains to be explored. METHODS: This study used the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to evaluate the association between BLT2 expression and the clinical outcome of ccRCC. Based on TIMER2.0, the correlation between BLT2 expression in ccRCC and tumor immune characteristics was evaluated. RESULTS: The expression of BLT2 in ccRCC was higher than that in normal tissues. Kaplan-Meier survival analysis indicated that high BLT2 expression was significantly correlated with poor overall survival (HR = 1.75, p < 0.001) and disease-specific survival (HR = 1.60, p = 0.014) for patients with ccRCC. In addition, our findings revealed that there was no significant correlation between the M1 marker genes and the expression of BLT2 in ccRCC, while moderate correlations were observed between the BLT2 expression and the M2 marker genes. Tregs and T cell exhaustion marker genes were positively correlated with BLT2 expression in ccRCC (p < 0.001). CONCLUSION: BLT2 may serve as a novel prognostic biomarker and is related to the shaping of tumor immune microenvironment in ccRCC. The expression of BLT2 potentially contributes to the regulation of TAMs, T cell exhaustion, and Tregs activation in ccRCC, providing new approaches to promote the development of new immunotherapeutic strategies for ccRCC.
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. According to reports, leukotriene B4 receptor 2 (LTB4R2, also known as BLT2), a chemokine receptor, is upregulated in different tumors. However, the correlation between BLT2 expression and its prognostic value in ccRCC remains to be explored. METHODS: This study used the The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to evaluate the association between BLT2 expression and the clinical outcome of ccRCC. Based on TIMER2.0, the correlation between BLT2 expression in ccRCC and tumor immune characteristics was evaluated. RESULTS: The expression of BLT2 in ccRCC was higher than that in normal tissues. Kaplan-Meier survival analysis indicated that high BLT2 expression was significantly correlated with poor overall survival (HR = 1.75, p < 0.001) and disease-specific survival (HR = 1.60, p = 0.014) for patients with ccRCC. In addition, our findings revealed that there was no significant correlation between the M1 marker genes and the expression of BLT2 in ccRCC, while moderate correlations were observed between the BLT2 expression and the M2 marker genes. Tregs and T cell exhaustion marker genes were positively correlated with BLT2 expression in ccRCC (p < 0.001). CONCLUSION: BLT2 may serve as a novel prognostic biomarker and is related to the shaping of tumor immune microenvironment in ccRCC. The expression of BLT2 potentially contributes to the regulation of TAMs, T cell exhaustion, and Tregs activation in ccRCC, providing new approaches to promote the development of new immunotherapeutic strategies for ccRCC.
Authors: Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole Journal: Eur Urol Date: 2015-08-19 Impact factor: 20.096
Authors: Denise R Minton; Leiping Fu; Nigel P Mongan; Maria M Shevchuk; David M Nanus; Lorraine J Gudas Journal: Clin Cancer Res Date: 2016-01-18 Impact factor: 12.531
Authors: Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon Journal: Cell Metab Date: 2018-05-10 Impact factor: 27.287
Authors: Shuchismita R Satpathy; Venkatakrishna R Jala; Sobha R Bodduluri; Elangovan Krishnan; Bindu Hegde; Gary W Hoyle; Mostafa Fraig; Andrew D Luster; Bodduluri Haribabu Journal: Nat Commun Date: 2015-04-29 Impact factor: 14.919
Authors: Thomas J Mitchell; Samra Turajlic; Andrew Rowan; David Nicol; James H R Farmery; Tim O'Brien; Inigo Martincorena; Patrick Tarpey; Nicos Angelopoulos; Lucy R Yates; Adam P Butler; Keiran Raine; Grant D Stewart; Ben Challacombe; Archana Fernando; Jose I Lopez; Steve Hazell; Ashish Chandra; Simon Chowdhury; Sarah Rudman; Aspasia Soultati; Gordon Stamp; Nicos Fotiadis; Lisa Pickering; Lewis Au; Lavinia Spain; Joanna Lynch; Mark Stares; Jon Teague; Francesco Maura; David C Wedge; Stuart Horswell; Tim Chambers; Kevin Litchfield; Hang Xu; Aengus Stewart; Reza Elaidi; Stéphane Oudard; Nicholas McGranahan; Istvan Csabai; Martin Gore; P Andrew Futreal; James Larkin; Andy G Lynch; Zoltan Szallasi; Charles Swanton; Peter J Campbell Journal: Cell Date: 2018-04-12 Impact factor: 41.582
Authors: R Hennig; T Osman; I Esposito; N Giese; S M Rao; X-Z Ding; W-G Tong; M W Büchler; T Yokomizo; H Friess; T E Adrian Journal: Br J Cancer Date: 2008-09-09 Impact factor: 7.640